

US009409984B2

(12) United States Patent

Giles-Komar et al.

(10) Patent No.:

US 9,409,984 B2

(45) **Date of Patent:**

*Aug. 9, 2016

(54) METHOD FOR TREATING PSORIASIS BY ADMINISTERING AN ANTI-IL-12 ANTIBODY

(71) Applicant: **Janssen Biotech, Inc.**, Horsham, PA

(US)

(72) Inventors: Jill Giles-Komar, Spring House, PA

(US); **David M. Knight**, Berwyn, PA (US); **David Peritt**, Lake Forest, IL (US); **Bernard Scallon**, Spring House, PA (US); **David Shealy**, Spring House,

PA (US)

(73) Assignee: **Janssen Biotech, Inc.**, Horsham, PA

(US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35 U.S.C. 154(b) by 210 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 14/190,893

(22) Filed: Feb. 26, 2014

(65) **Prior Publication Data**

US 2014/0178295 A1 Jun. 26, 2014

Related U.S. Application Data

- (62) Division of application No. 13/670,918, filed on Nov. 7, 2012, now Pat. No. 8,703,141, which is a division of application No. 13/299,874, filed on Nov. 18, 2011, now Pat. No. 8,329,171, which is a division of application No. 12/971,626, filed on Dec. 17, 2010, now Pat. No. 8,084,233, which is a division of application No. 12/500,120, filed on Jul. 9, 2009, now Pat. No. 7,887,807, which is a division of application No. 11/668,256, filed on Jan. 29, 2007, now Pat. No. 7,560,247, which is a division of application No. 10/975,883, filed on Oct. 28, 2004, now Pat. No. 7,279,157, which is a division of application No. 09/920,262, filed on Aug. 1, 2001, now Pat. No. 6,902,734.
- (60) Provisional application No. 60/223,358, filed on Aug. 7, 2000, provisional application No. 60/236,827, filed on Sep. 29, 2000.
- (51) Int. Cl.

 A61K 39/395 (2006.01)

 C07K 16/24 (2006.01)

 A61K 45/06 (2006.01)

 A61K 39/00 (2006.01)

(52) U.S. Cl.

(58) Field of Classification Search

(56) References Cited

U.S. PATENT DOCUMENTS

5,457,038 A	1	0/1995	Trinchieri et al.
5,547,852 A	1	8/1996	Seiler et al.
5,648,467 A	1	7/1997	Trinchieri et al.
5,780,597 A	1	7/1998	Gately et al.
5,811,523 A	1	9/1998	Trinchieri et al.
5,891,680 A	1	4/1999	Lieschke et al.
6,086,876 A	1	7/2000	Karp et al.
6,225,117 E	31	5/2001	Gately et al.
6,300,478 E	31 1	0/2001	Trinchieri et al.
6,338,848 E	31	1/2002	Leonard et al.
6,495,667 E	31 1	2/2002	Bazan
6,914,128 E	31	7/2005	Salfeld et al.

FOREIGN PATENT DOCUMENTS

CL	688-2000	3/2000
EP	0640689 A2	3/1995
EP	790255 A2	8/1997
EP	433827 B1	3/1998
EP	804581 B1	9/2001
EP	1 137 766 B1	9/2005
WO	WO 90/05147 A1	5/1990
WO	WO 92/05256 A1	4/1992
WO	WO 96/33735 A	10/1996
WO	WO 97/15327 A	5/1997
WO	WO 97/15327 A1	5/1997
WO	WO 99/37682 A2	7/1999
WO	WO 00/34459 A1	6/2000
WO	WO 00/56772 A1	9/2000
WO	WO 01/19373 A2	3/2001

OTHER PUBLICATIONS

Carter, et al., "Production and Characterization of Monoclonal Antibodies to Human Interleukin-12," Hybridoma, 16(4): 363-369

Casipit, et al., "Improving the binding affinity of an antibody using molecular modeling and site-directed mutagenesis," Protein Science, 7: 1671-1680 (1998).

Schildbach, et al., "Modulation of antibody affinity by a non-contact residue," Protein Science, 2: 206-214 (1993).

A. U. Gubler et. al (Coexpression of Two Distinct Genes is Required to Generate Secreted Bioactive Cytotoxic Lymphocyte Maturation Factor) Proc. Natl. acad. Sci. USA. vol. 88. pp. 4143-4147—(May 1991) Immunology.

A. U. Gubler et. al (Clonic and Expression of Cytotoxic Lymphocyte Maturation Factor (CLMF) a Heterodimeric Lymphokine That Potentiates NR. LAK NA D T-Cell Reponses) Abstracts Journal of celluar Biochemistry Supplement 15 F: 70 (1991).

(Continued)

Primary Examiner — Prema Mertz (74) Attorney, Agent, or Firm — Eric Dichter

(57) ABSTRACT

Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.

4 Claims, 12 Drawing Sheets